EBV DNA levels should be monitored in patients with high-risk features. Early treatment may be instituted at predefined DNA levels (preemptive approach) or at the earliest signs of LPD (prompt approach). Stepwise treatment guided by EBV DNA, including interruption of immunosuppression, rituximab, and adoptive T-cell immunotherapy may all add to the low mortality currently associated with LPD following allogeneic stem cell transplantation.

Additional Metadata
Keywords Allogeneic stem cell transplantation, Epstein-Barr virus, Epstein-Barr virus DNAemia, Epstein-Barr virus-associated lymphoproliferative disorders, Epstein-barr virus-specific cytotoxic T lymphocytes
Persistent URL dx.doi.org/10.1097/MOH.0b013e328311f438, hdl.handle.net/1765/14420
Journal Current Opinion in Hematology
Meijer, E, & Cornelissen, J.J. (2008). Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: Molecular monitoring and early treatment of high-risk patients. Current Opinion in Hematology (Vol. 15, pp. 576–585). doi:10.1097/MOH.0b013e328311f438